These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 32762128)

  • 41. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dynamic Changes of Circulating Tumor DNA Predict Clinical Outcome in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Weber S; van der Leest P; Donker HC; Schlange T; Timens W; Tamminga M; Hasenleithner SO; Graf R; Moser T; Spiegl B; Yaspo ML; Terstappen LWMM; Sidorenkov G; Hiltermann TJN; Speicher MR; Schuuring E; Heitzer E; Groen HJM
    JCO Precis Oncol; 2021 Nov; 5():1540-1553. PubMed ID: 34994642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
    Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
    Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
    Mezquita L; Preeshagul I; Auclin E; Saravia D; Hendriks L; Rizvi H; Park W; Nadal E; Martin-Romano P; Ruffinelli JC; Ponce S; Audigier-Valette C; Carnio S; Blanc-Durand F; Bironzo P; Tabbò F; Reale ML; Novello S; Hellmann MD; Sawan P; Girshman J; Plodkowski AJ; Zalcman G; Majem M; Charrier M; Naigeon M; Rossoni C; Mariniello A; Paz-Ares L; Dingemans AM; Planchard D; Cozic N; Cassard L; Lopes G; Chaput N; Arbour K; Besse B
    Eur J Cancer; 2021 Jul; 151():211-220. PubMed ID: 34022698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Morita A; Ichihara E; Inoue K; Fujiwara K; Yokoyama T; Harada D; Ando C; Kano H; Oda N; Tamura T; Ochi N; Kawai H; Inoue M; Hara N; Fujimoto N; Ichikawa H; Oze I; Hotta K; Maeda Y; Kiura K
    Int J Cancer; 2024 May; 154(9):1607-1615. PubMed ID: 38196128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
    Bilger G; Girard N; Doubre H; Levra MG; Giroux-Leprieur E; Giraud F; Decroisette C; Carton M; Massiani MA
    Cancer Immunol Immunother; 2022 Jul; 71(7):1719-1731. PubMed ID: 34821950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
    Cortellini A; Ricciuti B; Vaz VR; Soldato D; Alessi JV; Dall'Olio FG; Banna GL; Muthuramalingam S; Chan S; Majem M; Piedra A; Lamberti G; Andrini E; Addeo A; Friedlaender A; Facchinetti F; Gorría T; Mezquita L; Hoton D; Valerie L; Nana FA; Artingstall J; Comins C; Di Maio M; Caglio A; Cave J; McKenzie H; Newsom-Davis T; Evans JS; Tiseo M; D'Alessio A; Fulgenzi CAM; Besse B; Awad MM; Pinato DJ
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of Smoking History on the Effectiveness of Immune-checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer: Analysis of Real-world Data.
    Nakahama K; Izumi M; Yoshimoto N; Fukui M; Sugimoto A; Nagamine H; Ogawa K; Sawa K; Tani Y; Kaneda H; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
    Anticancer Res; 2023 May; 43(5):2185-2197. PubMed ID: 37097681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer.
    Hakozaki T; Richard C; Elkrief A; Hosomi Y; Benlaïfaoui M; Mimpen I; Terrisse S; Derosa L; Zitvogel L; Routy B; Okuma Y
    Cancer Immunol Res; 2020 Oct; 8(10):1243-1250. PubMed ID: 32847937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
    Hu X; Guo J; Shi J; Li D; Li X; Zhao W
    BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
    Flörsch B; Taugner J; Käsmann L; Kenndoff S; Guggenberger J; Tufman A; Reinmuth N; Duell T; Belka C; Eze C; Manapov F
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3267-3276. PubMed ID: 35915184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
    Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
    Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Jacobi O; Landman Y; Reinhorn D; Icht O; Sternschuss M; Rotem O; Finkel I; Allen AM; Dudnik E; Goldstein DA; Zer A
    Oncology; 2021; 99(9):555-561. PubMed ID: 34247166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
    Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
    Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.